Patents by Inventor Murad Ismail Inamdar

Murad Ismail Inamdar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10822308
    Abstract: The present invention relates to processes for the preparation of eluxadoline and its intermediates.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 3, 2020
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Kdv Jesunadh, Murad Ismail Inamdar, Mukesh Kumar Madhra
  • Patent number: 10479769
    Abstract: The present invention relates to processes for the preparation of eluxadoline. The present invention also provides a compound of Formula V, a process for its preparation, and its use for the preparation of eluxadoline.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 19, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Murad Ismail Inamdar, Sriram Hari Mohan, Ketan Vithalbhai Hirpara
  • Publication number: 20190248748
    Abstract: The present invention relates to processes for the preparation of eluxadoline. The present invention also provides a compound of Formula V, a process for its preparation, and its use for the preparation of eluxadoline.
    Type: Application
    Filed: September 20, 2017
    Publication date: August 15, 2019
    Inventors: Murad Ismail INAMDAR, Sriram Hari MOHAN, Ketan Vithalbhai HIRPARA
  • Publication number: 20190202793
    Abstract: The present invention relates to processes for the preparation of eluxadoline and its intermediates.
    Type: Application
    Filed: June 23, 2017
    Publication date: July 4, 2019
    Inventors: Kdv JESUNADH, Murad Ismail INAMDAR, Mukesh Kumar MADHRA
  • Publication number: 20150239909
    Abstract: The present invention relates to an improved and industrially advantageous process for the preparation of (1S, 4S, 5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one represented by the following formula (1) which is a key intermediate in the synthesis of edoxaban, a compound that exhibits on inhibitory effect on activated blood coagulation factor X (also referred to as activated factor X or FXa), and is useful as a preventive and/or therapeutic drug for thrombotic diseases. The process includes reacting (1S)-cyclohex-3-ene-1-carboxylic acid of formula (II) with a brominating agent selected from the group consisting of N-bromosuccinimide or 1,3-dibromo-5, 5-dimethylhydantoin in the presence of a base selected from calcium oxide or calcium hydroxide in a solvent selected from the group comprising of dicholoromethane, toluene, tetrahydrofuran, ethyl acetate, hexanes, cyclopentyl methyl ether (CPME) or a misture thereof to get (1S, 4S 5S)-4-bromo-6-oxabicyclo[3.2.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshitaka Nakamura, Kumar Madhra Mukesh, Murad Ismail Inamdar